Diabetes Islet Preservation Immune Treatment

Diabetes Islet Preservation Immune Treatment

Conditions: Diabetes Mellitus, Type 1; Hypoglycemia; Autoimmune Diseases; Diabetes Mellitus
Interventions: Drug: Anti-Thymocyte Globulin (ATG); Drug: Interleukin 2; Drug: Exenatide; Drug: Adalimumab; Other: ATG Placebo; Other: IL-2 Placebo; Other: Adalimumab Placebo; Other: Exenatide Placebo
Sponsors: Camillo Ricordi and Jay Skyler; Diabetes Research Institute Foundation
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 19, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments